Comparison of the outcomes of biliary atresia with cystic degeneration and isolated biliary atresia: A matched-pair analysis

J Pediatr Surg. 2020 Oct;55(10):2177-2182. doi: 10.1016/j.jpedsurg.2020.02.054. Epub 2020 Mar 3.

Abstract

Background: Patients with biliary atresia (BA) with extrahepatic cystic degeneration (BACD) have a unique pathophysiology; however, clinical outcomes and progression of perinatal degeneration are not well-defined. We aimed to investigate the differences in clinical characteristics and outcomes between BACD and isolated BA (IBA).

Methods: We performed a retrospective analysis of patients with BA who underwent Kasai portoenterostomy (KPE) from August 1997 to January 2018 and compared the clinical features and outcomes between BACD (n = 21) and IBA (n = 237). Matched-pair analysis for age and sex was performed between BACD and IBA groups to reduce confounding.

Results: Before matched-pair analysis, we found that BACD patients were younger at KPE (45 vs. 64 days, p = 0.008), showed lower total bilirubin at the 3-month follow-up (0.5 vs. 1.4 mg/dL, p = 0.002), and higher 5-year native liver survival rate (95.2% vs. 61.4%, p = 0.006) than IBA patients. After matching, the BACD group showed significantly lower total bilirubin levels at the 3-month follow-up (0.5 vs. 1.5 mg/dL, p = 0.036) and higher 5-year native liver survival rate (95.2% vs. 57.5%, p = 0.006) than the IBA group.

Conclusion: BACD demonstrated higher bilirubin clearance and native liver survival rates than IBA.

Levels of evidence: Treatment Study, Level III.

Keywords: Biliary atresia; Cystic degeneration; Kasai portoenterostomy; Liver fibrosis; Matching; Prognosis.

Publication types

  • Comparative Study

MeSH terms

  • Biliary Atresia / blood
  • Biliary Atresia / complications*
  • Biliary Atresia / surgery*
  • Bilirubin / blood
  • Cysts / blood
  • Cysts / complications*
  • Female
  • Humans
  • Infant
  • Liver / physiopathology
  • Liver Function Tests
  • Male
  • Matched-Pair Analysis
  • Portoenterostomy, Hepatic
  • Retrospective Studies
  • Survival Rate
  • Treatment Outcome

Substances

  • Bilirubin